Physician profile
Sandra Rubio
NPI 1225131014
$34,384.87
in general payments reported to CMS, 2019-2025
24 companies · $82.58 in 2025
The $82.58 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,972 · 2021: $8,201 · 2022: $714 · 2023: $6,560 · 2024: $242 · 2025: $82.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,800 · Travel and Lodging: $1,339 · Food and Beverage: $708 · Education: $38.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,800.00 |
| Travel and Lodging | $1,338.51 |
| Food and Beverage | $707.86 |
| Education | $38.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19,491.84 | 2019-2022 | |
| Horizon Therapeutics Plc | $8,731.60 | 2020-2023 | Tepezza |
| Corcept Therapeutics | $3,514.07 | 2019-2025 | Korlym |
| Amgen INC. | $469.58 | 2019-2022 | |
| Novo Nordisk INC | $428.71 | 2019-2025 | Ozempic |
| Medtronic, INC. | $313.98 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals Lp | $261.23 | 2019 | |
| Medtronic Minimed, INC. | $222.33 | 2019-2020 | |
| Abbott Laboratories | $215.21 | 2019-2021 | |
| Amarin Pharma, INC. | $173.01 | 2019-2020 | |
| Lilly USA, LLC | $127.35 | 2019-2022 | |
| Dexcom, INC. | $63.54 | 2020-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $62.92 | 2019 | |
| Xeris Pharmaceuticals, INC. | $60.23 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.34 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $47.76 | 2024 | |
| Insulet Corporation | $29.69 | 2019-2023 | Omnipod |
| Merck Sharp & Dohme LLC | $25.92 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $22.00 | 2023 | NP Thyroid 60 |
| Abbvie INC. | $19.27 | 2021 | |
| Tandem Diabetes Care, INC. | $14.21 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.80 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.16 | 2019 | |
| Ibsa Pharma INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rubio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.